Press releases

27 Jun 2023

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

26 Jun 2023

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

26 Jun 2023

Change in UCB’s Executive Committee

20 Jun 2023

UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress

7 Jun 2023

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

31 May 2023

New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023

Press releases

Press releases

Search Press releases

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Change in UCB’s Executive Committee

UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Change in UCB’s Executive Committee

UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023

Choose a Country